290 related articles for article (PubMed ID: 12825926)
1. Synthesis of 1-boraadamantaneamine derivatives with selective astrocyte vs C6 glioma antiproliferative activity. A novel class of anti-hepatitis C agents with potential to bind CD81.
Wagner CE; Mohler ML; Kang GS; Miller DD; Geisert EE; Chang YA; Fleischer EB; Shea KJ
J Med Chem; 2003 Jul; 46(14):2823-33. PubMed ID: 12825926
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
Allander T; Forns X; Emerson SU; Purcell RH; Bukh J
Virology; 2000 Nov; 277(2):358-67. PubMed ID: 11080483
[TBL] [Abstract][Full Text] [Related]
3. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells.
Koutsoudakis G; Herrmann E; Kallis S; Bartenschlager R; Pietschmann T
J Virol; 2007 Jan; 81(2):588-98. PubMed ID: 17079281
[TBL] [Abstract][Full Text] [Related]
4. Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients.
Hofmann WP; Sarrazin C; Kronenberger B; Schönberger B; Bruch K; Zeuzem S
J Infect Dis; 2003 Mar; 187(6):982-7. PubMed ID: 12660945
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein.
Heo TH; Lee SM; Bartosch B; Cosset FL; Kang CY
Virus Res; 2006 Oct; 121(1):58-64. PubMed ID: 16725222
[TBL] [Abstract][Full Text] [Related]
6. Structural modifications of salicylates: inhibitors of human CD81-receptor HCV-E2 interaction.
Holzer M; Ziegler S; Neugebauer A; Kronenberger B; Klein CD; Hartmann RW
Arch Pharm (Weinheim); 2008 Aug; 341(8):478-84. PubMed ID: 18618487
[TBL] [Abstract][Full Text] [Related]
7. The roles of CD81 and glycosaminoglycans in the adsorption and uptake of infectious HCV particles.
Morikawa K; Zhao Z; Date T; Miyamoto M; Murayama A; Akazawa D; Tanabe J; Sone S; Wakita T
J Med Virol; 2007 Jun; 79(6):714-23. PubMed ID: 17457918
[TBL] [Abstract][Full Text] [Related]
8. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry.
Voisset C; Lavie M; Helle F; Op De Beeck A; Bilheu A; Bertrand-Michel J; Tercé F; Cocquerel L; Wychowski C; Vu-Dac N; Dubuisson J
Cell Microbiol; 2008 Mar; 10(3):606-17. PubMed ID: 17979982
[TBL] [Abstract][Full Text] [Related]
9. A conserved Gly436-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry.
Drummer HE; Boo I; Maerz AL; Poumbourios P
J Virol; 2006 Aug; 80(16):7844-53. PubMed ID: 16873241
[TBL] [Abstract][Full Text] [Related]
10. CD81 regulates neuron-induced astrocyte cell-cycle exit.
Kelić S; Levy S; Suarez C; Weinstein DE
Mol Cell Neurosci; 2001 Mar; 17(3):551-60. PubMed ID: 11273649
[TBL] [Abstract][Full Text] [Related]
11. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry.
Liu R; Tewari M; Kong R; Zhang R; Ingravallo P; Ralston R
Antiviral Res; 2010 May; 86(2):172-9. PubMed ID: 20156485
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, X-ray crystal structure study, and cytostatic and antiviral evaluation of the novel cycloalkyl-N-aryl-hydroxamic acids.
Barbarić M; Ursić S; Pilepić V; Zorc B; Hergold-Brundić A; Nagl A; Grdisa M; Pavelić K; Snoeck R; Andrei G; Balzarini J; De Clercq E; Mintas M
J Med Chem; 2005 Feb; 48(3):884-7. PubMed ID: 15689173
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors.
Ziegler S; Kronenberger B; Albrecht BA; Kaul A; Gamer AL; Klein CD; Hartmann RW
J Biomol Screen; 2009 Jul; 14(6):620-6. PubMed ID: 19531666
[TBL] [Abstract][Full Text] [Related]
14. Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81.
Cao J; Zhao P; Miao XH; Zhao LJ; Xue LJ; Qi Zt Zt
Cell Res; 2003 Dec; 13(6):473-9. PubMed ID: 14728804
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus (HCV): a review of immunological aspects.
Irshad M; Khushboo I; Singh S; Singh S
Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
[TBL] [Abstract][Full Text] [Related]
16. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.
Rosa D; Saletti G; De Gregorio E; Zorat F; Comar C; D'Oro U; Nuti S; Houghton M; Barnaba V; Pozzato G; Abrignani S
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18544-9. PubMed ID: 16339892
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity.
Chan-Fook C; Jiang WR; Clarke BE; Zitzmann N; Maidens C; McKeating JA; Jones IM
Virology; 2000 Jul; 273(1):60-6. PubMed ID: 10891408
[TBL] [Abstract][Full Text] [Related]
18. Primary hepatocytes of Tupaia belangeri as a potential model for hepatitis C virus infection.
Zhao X; Tang ZY; Klumpp B; Wolff-Vorbeck G; Barth H; Levy S; von Weizsäcker F; Blum HE; Baumert TF
J Clin Invest; 2002 Jan; 109(2):221-32. PubMed ID: 11805134
[TBL] [Abstract][Full Text] [Related]
19. Association of hepatitis C virus envelope proteins with exosomes.
Masciopinto F; Giovani C; Campagnoli S; Galli-Stampino L; Colombatto P; Brunetto M; Yen TS; Houghton M; Pileri P; Abrignani S
Eur J Immunol; 2004 Oct; 34(10):2834-42. PubMed ID: 15368299
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus infection in mouse hepatoma cells co-expressing human CD81 and Sip-L.
Yeh CT; Lai HY; Yeh YJ; Cheng JC
Biochem Biophys Res Commun; 2008 Jul; 372(1):157-61. PubMed ID: 18474223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
